Adaptive Design in Early-Phase Oncology Trials – Best Practices for Conduct

Publish Date:
November 12, 2014
Connie Wierman, MBA, Vice President, Biopharmaceutical Development, Jeff Joseph, Senior Director, Statistics, Scott Currence, Director, Service Partnerships, Howard Grossberg, M.D., President, Grossberg Pharmaceutical Consulting and Senior Oncology Medical Advisor

Adaptive design enables researchers to make trial modifications at interim stages by using accumulating information as trials progress. In this webinar, Chiltern experts will discuss adaptive design in early-phase oncology trials. Best practices for development and trial management will be shared. We’ll review:

  • an understanding of the principles of choosing an appropriate adaptive design for early-stage oncology trials and the management of specific issues that arise
  • best practices to manage site-specific issues, including data entry, preservation of patient safety
  • best practices for dealing with statistical, regulatory and operational considerations involved with adaptive design in early-stage oncology trials.